BRAF V600E	Hairy Cell Leukemia	BRAF V600E	Hairy Cell Leukemia	trametinib + dabrafenib Sensitive: C3 – Early Trials Blood - 1 week (New C3) trametinib + dabrafenib Sensitive : C3 Blood - 1wk	trametinib + dabrafenib Sensitive: C3 – Early Trials Blood - 1 week trametinib + dabrafenib Sensitive : C3 Blood - 1 week - (New C3)
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	cladribine Sensitive: A1 - Approval cladribine Sensitive : A1	cladribine Sensitive: A1 - Approval cladribine Sensitive : A1
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	moxetumomab pasudotox Sensitive: A1 - Approval moxetumomab pasudotox Sensitive : A1	moxetumomab pasudotox Sensitive: A1 - Approval moxetumomab pasudotox Sensitive : A1
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	vemurafenib + rituximab Sensitive: A2 - Guideline vemurafenib + rituximab Sensitive : A2	vemurafenib + rituximab Sensitive: A2 - Guideline vemurafenib + rituximab Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	pentostatin Sensitive: A2 - Guideline pentostatin Sensitive : A2	pentostatin Sensitive: A2 - Guideline pentostatin Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	rituximab/hyaluronidase Sensitive: A2 - Guideline rituximab / hyaluronidase Sensitive : A2	rituximab/hyaluronidase Sensitive: A2 - Guideline rituximab / hyaluronidase Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
BRAF V600E	Hairy Cell Leukemia	BRAF V600E	Hairy Cell Leukemia	dabrafenib Sensitive: C2 – Inclusion Criteria dabrafenib Sensitive : C2	dabrafenib Sensitive: C2 – Inclusion Criteria dabrafenib Sensitive : C2
BRAF V600	Hairy Cell Leukemia	BRAF V600	Hairy Cell Leukemia	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF V600E	Hairy Cell Leukemia	BRAF V600E	Hairy Cell Leukemia	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF V600E	Hairy Cell Leukemia	BRAF V600E	Hairy Cell Leukemia	dabrafenib + rituximab Sensitive: C3 – Early Trials dabrafenib + rituximab Sensitive : C3	dabrafenib + rituximab Sensitive: C3 – Early Trials dabrafenib + rituximab Sensitive : C3
TP53 mutation	Hairy Cell Leukemia	TP53 mutation	Hairy Cell Leukemia	rituximab + cladribine Resistant: C3 – Early Trials rituximab + cladribine Resistant : C3	rituximab + cladribine Resistant: C3 – Early Trials rituximab + cladribine Resistant : C3
MYD88 L265P + BRAF V600E	Hairy Cell Leukemia	MYD88 L265P + BRAF V600E	Hairy Cell Leukemia	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
KRAS mutation	Hairy Cell Leukemia	KRAS mutation	Hairy Cell Leukemia	vemurafenib Resistant: C4 – Case Studies vemurafenib Resistant : C4	vemurafenib Resistant: C4 – Case Studies vemurafenib Resistant : C4

Hairy Cell Leukemia

Associations(18)

Associations
(18)